Detalles de la búsqueda
1.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res
; 24(1): 58, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36056374
2.
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
Breast Cancer Res
; 23(1): 36, 2021 03 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33736679
3.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Int J Cancer
; 148(10): 2614-2627, 2021 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533487
4.
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Breast Cancer Res
; 22(1): 47, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32408905
5.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int J Cancer
; 146(1): 262-271, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31162838
6.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30632020
7.
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Breast Cancer Res Treat
; 173(2): 319-328, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30324275
8.
Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer.
Future Oncol
; 15(16): 1921-1938, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31140870
9.
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Lancet
; 389(10087): 2430-2442, 2017 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27939063
10.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28664507
11.
Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age.
Ann Surg Oncol
; 24(3): 698-704, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27783163
12.
Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy.
Strahlenther Onkol
; 193(1): 62-69, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27858093
13.
Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?
Lancet Oncol
; 22(1): 5-6, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33357419
14.
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Int J Cancer
; 139(4): 882-9, 2016 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26946057
15.
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
Int J Cancer
; 137(12): 2981-8, 2015 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26100253
16.
The prognostic impact of age in different molecular subtypes of breast cancer.
Breast Cancer Res Treat
; 152(3): 667-73, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26195120
17.
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Breast Cancer Res Treat
; 150(2): 279-88, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25721604
18.
New treatment strategies for patients with triple-negative breast cancer.
Curr Opin Obstet Gynecol
; 27(1): 77-84, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25502428
19.
Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
Mol Cancer
; 13: 174, 2014 Jul 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-25033833
20.
Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.
Arch Gynecol Obstet
; 290(6): 1221-9, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25012601